NIPPON SHINYAKU

NIPPON SHINYAKU

Chairman: Shigenobu Maekawa

Nippon Shinyaku_logo

Nippon Shinyaku Co., Ltd. manufactures pharmaceutical and health foods products. The Company produces drugs for urinary, nerve, respiratory, and circulatory systems as well as analgesic and anti-inflammatory drugs. Nippon Shinyaku also develops synthetic anti-bacterial agents.


More informations about "Nippon Shinyaku" on Search Engine

NIPPON SHINYAKU CO., LTD.

March 18, 2021. (Media)Nippon Shinyaku and Menarini Group enter into an Exclusive License Agreement to Develop and Commercialize tagraxofusp in Japan. March 16, 2021. (Media)Nippon Shinyaku Announces Changes to Representative Directors and Members of โ€ฆ

Nippon-shinyaku.co.jp Go URL

Financial Information | Investor Relations | NIPPON ...

Company Profile. Company Profile Video. Board of Directors, Corporate Officers and Corporate Auditors. Company History. Offices, Plants & Laboratories. Nippon Shinyaku by AERA (Brochuer) News Release. Corporate Social Responsibility. Basic CSR Policies and Promotional System.

Nippon-shinyaku.co.jp Go URL

Contact Information | NIPPON SHINYAKU CO., LTD.

Contact Information. Please read the following before you send an inquiry to us. The personal information you filled out below is only used for the reply to you. Since some inquiries may require some days to be answered depending on the subjects, we may not be able to meet the requested deadline.

Nippon-shinyaku.co.jp Go URL

Financial Information - nippon-shinyaku.co.jp

May 14, 2021ย ยท Nippon Shinyaku: Phase III: ZX008: intractable diseaseใƒปorphan disease: Dravet syndrome Lennox-Gastaut syndrome: Licensed - in from Zogenix, Inc. Zogenix, Inc. Phase II: NS-304 (selexipag) cardiovascular: arteriosclerosis obliterans: Nippon Shinyaku: Nippon Shinyaku: Phase II: NS-304 (selexipag) orthopedics: lumbar spinal stenosis: Nippon ...

Nippon-shinyaku.co.jp Go URL

Who we Are - NS Pharma

Building upon a 100-year legacy Our corporate philosophy is derived from the extensive history and established relationships of our parent company, Nippon Shinyaku. We continue to build upon the legacy of Nippon Shinyaku to make a lasting, positive impact on all stakeholders.

Nspharma.com Go URL

Nippon Shinyaku Company Profile: Stock Performance ...

Nippon Shinyaku General Information Description. Nippon Shinyaku Co Ltd is a specialty and generic drug manufacturing company. Nippon's research and development activities include a focus on pharmaceuticals, nutraceuticals, safety and pharmacokinetics of drug seeds, genomic drug discovery, and nucleic acid drugs.

Pitchbook.com Go URL

Nippon Shinyaku Co Ltd - Company Profile and News ...

Company profile page for Nippon Shinyaku Co Ltd including stock price, company news, press releases, executives, board members, and contact information

Bloomberg.com Go URL

Pipeline Developments - NS Pharma

Nippon Shinyaku Co., Ltd. has been developing compounds in several therapeutic fields, including hematologic malignancies and intractable/orphan diseases. NS Pharma, Inc. has been developing NS-018 (for myelofibrosis) and NS-065/NCNP-01 (for Duchenne muscular dystrophy) on behalf of Nippon Shinyaku Co., Ltd.

Nspharma.com Go URL

NEWS RELEASE - NS Pharma

For additional safety information, please see the full Prescribing Information. About NS Pharma, Inc. NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.

Nspharma.com Go URL

Zogenix Enters Exclusive Distribution Agreement with ...

Mar 19, 2019ย ยท EMERYVILLE, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has entered into an exclusive distribution agreement with Nippon Shinyaku, Co., Ltd., a leading Japanese pharmaceutical product developer and distributor, for the commercialization of its lead product โ€ฆ

Zogenixinc.gcs-web.com Go URL

NIPPON SHINYAKU CO (NPPNY) Company Profile & Facts - Yahoo ...

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and โ€ฆ

Finance.yahoo.com Go URL

Viltepso A Treatment Against DMD - VILTEPSO

There is an ongoing study to confirm the clinical benefit of VILTEPSO. If you are a healthcare provider who treats patients with DMD. Learn More >. If you are a PATIENT or a Caregiver of a child with DMD. Discover Viltepso >. 833-NSSUPRT (833-677-8778) Mondayโ€“Friday, 8 AM-8 PM ET.

Viltepso.com Go URL

Nippon Shinyaku: Viltolarsen Update | Duchenne Muscular ...

Jun 15, 2020ย ยท This compound is being developed by Nippon Shinyaku and its subsidiary in the US NS pharma. The phase three clinical trial is currently recruiting ambulatory boys 4-7 years old. There is presently one Canadian site listed in Calgary. For more information on locations and eligibility, we encourage you to speak to your neuromuscular team and go to:

Jessesjourney.com Go URL

NIPPON SHINYAKU CO (NPPNY) Stock Price, News, Quote ...

Find the latest NIPPON SHINYAKU CO (NPPNY) stock quote, history, news and other vital information to help you with your stock trading and investing.

Finance.yahoo.com Go URL

[History of the Nippon Shinyaku Institute for Botanical ...

Author information: (1)The Nippon Shinyaku Institute for Botanical Research, Nippon Shinyaku Co., Ltd. [email protected] Soon after its foundation in 1919, Nippon Shinyaku Co., Ltd began to develop the domestic production of Santonin, an anthelmintic agent, which, until then, had been totally imported from Russia.

Ncbi.nlm.nih.gov Go URL

Nippon Shinyaku Co., Ltd. (4516 : TYO) Stock Price & News ...

Get the latest Nippon Shinyaku Co., Ltd. (4516) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Google.com Go URL

Review - Food and Drug Administration

Nippon Shinyaku Co., Ltd. submitted a New Drug Application (NDA 212154) for viltolarsen (VILTEPSO) for the treatment of Duchenne Muscular Dystrophy (DMD) in patients with a confirmed DMD mutation amenable to exon 53 skipping. DMD is a rare genetic neuromuscular disease affecting males and is

Accessdata.fda.gov Go URL

Jazz Pharmaceuticals and Nippon Shinyaku Enter Into ...

Mar 30, 2017ย ยท Under the terms of the agreements, Nippon Shinyaku will receive exclusive rights to develop and commercialize Defitelio and Vyxeos in Japan in return for an upfront payment to Jazz Pharmaceuticals and subsequent payments based on the successful achievement of certain regulatory and commercial milestones.

Investor.jazzpharma.com Go URL

Nippon Kayaku - Wikipedia

Nippon Kayaku (ๆ—ฅๆœฌๅŒ–่–ฌๆ ชๅผไผš็คพ, Nihon Kayaku Kabushiki-gaisha) (Japan Pharmaceuticals) is a Japanese company that was founded in 1916 as the first industrial explosives manufacturer in Japan under the company name Nippon Kayaku Seizo Co., Ltd.. Its main business areas are functional chemicals, pharmaceuticals, safety systems and agrochemicals.

En.wikipedia.org Go URL

Contact Us - NS Pharma

NS Pharma, Inc. 140 East Ridgewood Ave, Suite 280S Paramus, NJ 07652. For general information about NS Pharma: Phone: 1-866-NSPHARM (1-866-677-4276)

Nspharma.com Go URL